Research Laboratory of Dendrimers and Natural Polymers, Faculty of Chemistry, University of Tabriz, P.O. Box 51666, Tabriz, Iran.
Research Laboratory of Dendrimers and Natural Polymers, Faculty of Chemistry, University of Tabriz, P.O. Box 51666, Tabriz, Iran; Research Center for Pharmaceutical Nanotechnology (RCPN), Tabriz University of Medical Science, Tabriz, Iran.
Int J Biol Macromol. 2020 Dec 1;164:2301-2311. doi: 10.1016/j.ijbiomac.2020.08.121. Epub 2020 Aug 14.
Biocompatible drug delivery vehicles with sustained drug release property are valuable in cancer therapy and can reduce some of the side effects. Hence, to achieve the biocompatible system with sustained drug release behavior a new drug carrier was fabricated via in situ synthesis of MIL-53 (MIL = Materials of Institute Lavoisier) within the carboxymethylcellulose/graphene quantum dots matrix (CMC/GQDs) as a biological macromolecule based platform (MIL-53@CMC/GQDs). Fourier transform infrared (FT-IR), and X-ray diffraction (XRD) analysis revealed successful synthesis of MIL-53@CMC/GQDs. The mean pore diameter of MIL-53@CMC/GQDs obtained 18.66 nm. Scanning electron microscopy (SEM) and energy-dispersive X-ray spectroscopy (EDX) exhibited that MIL-53 is well distributed in hydrogel matrix. Doxorubicin (DOX) was loaded about 55.80% and 88.90% into the MIL-53 and MIL-53@CMC/GQDs, respectively. Drug release studies showed the pH-dependent DOX release behavior for DOX@MIL-53@CMC/GQDs. The cytotoxic assay approved the biocompatibility of MIL-53@CMC/GQDs against the human breast cancer cell line (MDA-MB 231). The fragmentation of nuclei and condensation of chromatin after treatment with DOX@MIL-53@CMC/GQDs displayed its capability in cancer treatment. Moreover, an arrest in sub-G1 of cell cycle after treatment with MIL-53@CMC/GQDs showed cell's apoptosis. The results conveyed a new concept that the MIL-53@CMC/GQDs could be proposed as a potential carrier for the delivery.
具有持续药物释放性能的生物相容药物输送载体在癌症治疗中很有价值,可减少一些副作用。因此,为了实现具有持续药物释放行为的生物相容系统,通过在羧甲基纤维素/石墨烯量子点基质(CMC/GQDs)内原位合成 MIL-53(MIL = Lavoisier 研究所材料)来制备新的药物载体作为基于生物大分子的平台(MIL-53@CMC/GQDs)。傅里叶变换红外(FT-IR)和 X 射线衍射(XRD)分析表明成功合成了 MIL-53@CMC/GQDs。MIL-53@CMC/GQDs 的平均孔径为 18.66nm。扫描电子显微镜(SEM)和能谱(EDX)显示 MIL-53 均匀分布在水凝胶基质中。阿霉素(DOX)分别负载到 MIL-53 和 MIL-53@CMC/GQDs 中约 55.80%和 88.90%。药物释放研究表明,DOX@MIL-53@CMC/GQDs 具有 pH 依赖性的 DOX 释放行为。细胞毒性试验证实了 MIL-53@CMC/GQDs 对人乳腺癌细胞系(MDA-MB 231)的生物相容性。用 DOX@MIL-53@CMC/GQDs 处理后细胞核碎裂和染色质浓缩显示其在癌症治疗中的能力。此外,用 MIL-53@CMC/GQDs 处理后细胞周期停滞在亚 G1 期表明细胞凋亡。结果传达了一个新概念,即 MIL-53@CMC/GQDs 可以作为潜在的载体用于药物输送。